Understanding TERT promoter mutations: A common path to immortality

Molecular Cancer Research

Volumn 14, Issue 4, 2016, Pages 315-323

  Bell, Robert J A ^a   Rube, H Tomas ^b   Xavier Magalhães, Ana ^a,c,d   Costa, Bruno M ^c,d   Mancini, Andrew ^a   Song, Jun S ^e   Costello, Joseph F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF MINHO   (Portugal)

^d UNIVERSITY OF MINHO   (Portugal)

^e UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ALLELE; BLADDER CANCER; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; CUTANEOUS MELANOMA; DNA SEQUENCE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HEMATOPOIETIC STEM CELL; HUMAN; LARYNX TUMOR; LEUKOCYTE; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MCF 7 CELL LINE; MEDULLOBLASTOMA; MELANOMA; NEUROBLASTOMA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SITE DIRECTED MUTAGENESIS; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; STEM CELL; THYROID CANCER; THYROID CARCINOMA; TRANSCRIPTION INITIATION; UROGENITAL TRACT CANCER; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; GERMLINE MUTATION; METABOLISM; MUTATION; TELOMERE HOMEOSTASIS;

BIOMARKERS, TUMOR; CARCINOGENESIS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HUMANS; MUTATION; PROMOTER REGIONS, GENETIC; TELOMERASE; TELOMERE HOMEOSTASIS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84963856937     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-16-0003     Document Type: Review

References (142)

1. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 1988; 85:6622-26.
2. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005;6:611-22.
3. Bryan TM, Cech TR. Telomerase and the maintenance of chromosome ends. Curr Opin Cell Biol 1999;11:318-24.
4. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in tetrahymena extracts. Cell 1985;43:405-13.
5. Weinrich SLS, Pruzan RR, Ma LL, Ouellette MM, Tesmer VMV, Holt SES, et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997; 17:498-502.
6. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-9.
7. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-95.
8. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 1997;6:2011-9.
9. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961;25:585-621.
10. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
11. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol 2000;1:72-6.
12. Cong Y-S, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002;66:407-25.
13. Nandakumar J, Cech TR. Finding the end: recruitment of telomerase to telomeres. Nat Rev Mol Cell Biol 2013;14:69-82.
14. Huschtscha LI, Holliday R. Limited and unlimited growth of SV40-transformed cells from human diploid MRC-5 fibroblasts. J Cell Sci 1983;63:77-99.
15. Wright WE, Pereira-Smith OM, Shay JW. Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol Cell Bio 1989;9:3088-92.
16. Counter CM, Avilion AA, Le Feuvre CE, Stewart NG, Greider CW, Harley CB, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992;11:1921-9.
17. Hiyama E, Tatsumoto N, Kodama T, Hiyama K, Shay J, Yokoyama T. Telomerase activity in human intestine. Int J Oncol 1996;9: 453-8.
18. Yui J, Chiu CP, Lansdorp PM. Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood 1998;91:3255-62.
19. Castelo-Branco P, Choufani S, Mack S, Gallagher D, Zhang C, Lipman T, et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol 2013;14:534-42.
20. Shay JW, Bacchetti S. Asurvey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
21. Murnane JP, Sabatier L, Marder BA, Morgan WF. Telomere dynamics in an immortal human cell line. EMBO J 1994;13:4953-62.
22. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995;14:4240-8.
23. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997;3:1271-4.
24. Walsh KM, Wiencke JK, Lachance DH, Wiemels JL, Molinaro AM, Eckel-Passow JE, et al. Telomere maintenance and the etiology of adult glioma. Neuro Oncol 2015;17:1445-52.
25. Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 2014;46:731-5.
26. Wrensch M, Jenkins RB, Chang JS, Yeh R-F, Xiao Y, Decker PA, et al. Variants in the CDKN2B and RTEL1 regions are associated with highgrade glioma susceptibility. Nat Genet 2009;41:905-8.
27. Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, Mccoy LS, et al. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget 2015;6:42468-77.
28. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009;41:221-7.
29. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008; 40:1404-6.
30. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008;40:1407-9.
31. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, et al. Agenome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010;42:224-8.
32. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339:959-61.
33. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339:957-9.
34. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013;110:6021-6.
35. Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 2013;73:1-18.
36. Quaas A, Oldopp T, Tharun L, Klingenfeld C, Krech T, Sauter G, et al. Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch 2014;465:673-7.
37. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, et al. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 2015;347:1006-10.
38. Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet 2015;47:1411-4.
39. Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 2015;526:700-4.
40. Bell RJA, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 2015;348:1036-9.
41. Zhu C-Q, Cutz J-C, Liu N, Lau D, Shepherd FA, Squire JA, et al. Amplification of telomerase (hTERT) gene is a poor prognostic marker in nonsmall-cell lung cancer. Br J Cancer 2006;94:1452-9.
42. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet 2008;182:1-11.
43. Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun 2013; 4:2185-5.
44. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013;4:2218.
45. Wang N, Liu T, Sofiadis A, Juhlin CC, Zedenius J, Höög A, et al. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer 2014;120: 2965-79.
46. Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V, et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun 2014;5:3401.
47. Hosler GA, Davoli T, Mender I, Litzner B, Choi J, Kapur P, et al. A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERT. J Cutan Pathol 2015;42:108-17.
48. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med 2015;373:1926-36.
49. Scott GA, Laughlin TS, Rothberg PG. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol 2014;27:516-23.
50. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 2013;126:267-76.
51. Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM. Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife 2015:1-20.
52. Azouz A, Wu Y-L, Hillion J, Tarkanyi I, Karniguian A, Aradi J, et al. Epigenetic plasticity of hTERT gene promoter determines retinoid capacity to repress telomerase in maturation-resistant acute promyelocytic leukemia cells. Leukemia 2010;24:613-22.
53. Stern JL, Theodorescu D, Vogelstein B, Papadopoulos N, Cech TR. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERTexpression in multiple cancers. Genome Res 2015; 29:2219-24.
54. Mosrati MA, Malmström A, Lysiak M, Krysztofiak A, Hallbeck M, Milos P, et al. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 2015;6:16663-73.
55. Beesley J, Pickett HA, Johnatty SE, Dunning AM, Chen X, Li J, et al. Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS One 2011;6: e24987-7.
56. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013;45:371-2.
57. Yoo SS, Do SK, Choi JE, Lee SY, Lee J, Cha SI, et al. TERT polymorphism rs2853669 influences on lung cancer risk in the Korean population. J Korean Med Sci 2015;30:1423-8.
58. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A 2013;110:17426-31.
59. Hosen I, Rachakonda PS, Heidenreich B, de Verdier PJ, Ryk C, Steineck G, et al. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int J Cancer 2015;137:1621-9.
60. Spiegl-Kreinecker S, Lotsch D, Ghanim B, Pirker C, Mohr T, Laaber M, et al. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol 2015;17:1231-40.
61. Labussière M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, et al. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 2014;111:2024-32.
62. Mosrati MA, Malmström A, Lysiak M, Krysztofiak A, Hallbeck M, Milos P, et al. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 2015;6:16663-73.
63. Nencha U, Rahimian A, Giry M, Sechi A, Mokhtari K, Polivka M, et al. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas. J Neurooncol 2016:126:441-6.
64. Remke M, Ramaswamy V, Peacock J, Shih DJH, Koelsche C, Northcott PA, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 2013;126:917-29.
65. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 2014;99:E754-65.
66. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 2014;33:4978-84.
67. George JR, Henderson YC, Williams MD, Roberts DB, Hei H, Lai SY, et al. Association of TERT promoter mutation, but not BRAF mutation, with increased mortality in PTC. J Clin Endocrinol Metab 2015;100: E1550-9.
68. Wu S, Huang P, Li C, Huang Y, Li X, Wang Y, et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. Eur Urol 2014;65:274-7.
69. Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst 2014;106: dju246.
70. Pópulo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, et al. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol 2014;134:2251-7.
71. Qu Y, Dang S, Wu K, Shao Y, Yang Q, Ji M, et al. TERT promoter mutations predict worse survival in laryngeal cancer patients. Int J Cancer 2014; 135:1008-10.
72. Wang K, Liu T, Liu C, Meng Y, Yuan X, Liu L, et al. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer. Oncologist 2015;20:263-9.
73. Wang K, Liu T, Ge N, Liu L, Yuan X, Liu J, et al. TERT promoter mutations are associated with distantmetastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive cast PCR. Oncotarget 2014;5:12428-39.
74. Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 2014;65:367-9.
75. Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, Bioulac-Sage P, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 2014;60: 1983-92.
76. Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol 2014;24:184-9.
77. Cheng KA, Kurtis B, Babayeva S, Zhuge J, Tantchou I, Cai D, et al. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites. Ann Diagn Pathol 2015;19:146-8.
78. Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 2014;5: 1515-25.
79. Labussière M, Boisselier B, Mokhtari K, Di Stefano A-L, Rahimian A, Rossetto M, et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 2014;83: 1200-6.
80. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015;372:2499-508.
81. The Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372:2481-98.
82. Wei G-H, Badis G, Berger MF, Kivioja T, Palin K, Enge M, et al. Genomewide analysis of ETS-family DNA-binding in vitro and in vivo. The EMBO Journal 2010;29:2147-60.
83. Thompson CC, Brown TA, Mcknight SL. Convergence of Ets- and notchrelated structural motifs in a heteromeric DNA binding complex. Science 1991;253:762-8.
84. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003;303:11-34.
85. La Marco K, Thompson CC, Byers BP, Walton EM, Mcknight SL. Identification of Ets- and notch-related subunits in GA binding protein. Science 1991;253:789-92.
86. Li Y, Zhou Q-L, Sun W, Chandrasekharan P, Cheng HS, Ying Z, et al. Noncanonical NF-kB signalling and ETS1/2 cooperatively drive C250Tmutant TERT promoter activation. Nat Cell Biol 2015;17:1327-38.
87. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999;21:220-4.
88. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, et al. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2000;28: 669-77.
89. Goueli BS, Janknecht R. Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. Oncogene 2003;22: 8042-7.
90. Xiao X, Athanasiou M, Sidorov IA, Horikawa I, Cremona G, Blair D, et al. Role of Ets/Id proteins for telomerase regulation in human cancer cells. Exp Mol Pathol 2003;75:238-47.
91. Xu D, Dwyer J, Li H, Duan W, Liu J-P. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J Biol Chem 2008;283:23567-80.
92. Wu H, Xiao Y, Zhang S, Ji S, Wei L, Fan F, et al. The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense. Cell Rep 2013;3:1663-77.
93. Flory E, Hoffmeyer A, Smola U, Rapp UR, Bruder JT. Raf-1 kinase targets GA-binding protein in transcriptional regulation of the human immunodeficiency virus type 1 promoter. J Virol 1996;70: 2260-8.
94. Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat. Rev 2013;39:444-56.
95. Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, andmetastasis of breast cancer. Clin Cancer Res 2006;12:3184-92.
96. Goldblatt EM, Gentry ER, Fox MJ, Gryaznov SM, Shen C, Herbert B-S. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Mol Cancer Ther 2009;8:2027-35.
97. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH, et al. New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 2008;10: 112-20.
98. Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010;16:154-63.
99. Joseph I, Tressler R, Bassett E, Harley C, Buseman CM, Pattamatta P, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 2010;70:9494-504.
100. Djojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 2005;42:1127-36.
101. Kozloff M, Sledge GW, Benedetti FM, Starr A. Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2010.
102. Chiappori AA, Kolevska T, Spigel DR, Hager S, Rarick M, Gadgeel S, et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann Oncol 2015;26:354-62.
103. Salloum R, Hummel T, Kumar SS, Dorris K, Li S, Lin T, et al. TR-11. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system (CNS) malignancies: a pediatric brain tumor consortium study. Neuro Oncol 2015;17:iii39-9.
104. Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015;373:908-19.
105. Miao Y, Wang R, Ju H, Ren G, Guo W, Lyu J. TERT promoter mutation is absent in oral mucosal melanoma. Oral Oncol 2015;51:e65-6.
106. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DTW, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 2013;126:907-15.
107. Vail E, Zheng X, Zhou M, Yang X, Fallon JT, Epstein JI, et al. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder. Ann Diagn Pathol 2015;19:301-5.
108. Huang D-S, Wang Z, He X-J, Diplas BH, Yang R, Killela PJ, et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 2015;51:969-76.
109. Koelsche C, Renner M, Hartmann W, Brandt R, Lehner B, Waldburger N, et al. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J Exp Clin Cancer Res 2014;33:33.
110. Wu R-C, Ayhan A, Maeda D, Kim K-R, Clarke BA, Shaw P, et al. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol 2014;232:473-81.
111. Papathomas TG, Oudijk L, Zwarthoff EC, Post E, Duijkers FA, van Noesel MM, et al. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. Endocr Relat Cancer 2014;21:653-61.
112. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013;20:603-10.
113. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 2013:1-5.
114. Nonoguchi N, Ohta T, Oh J-E, Kim Y-H, Kleihues P, Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 2013;126:931-7.
115. Griewank KG, Murali R, Schilling B, Scholz S, Sucker A, Song M, et al. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer 2013;109:497-501.
116. Liu X, Wu G, Shan Y, Hartmann C, Deimling von A, Xing M. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 2013;12:1637-8.
117. Tallet A, Nault J-C, Renier A, Hysi I, Galateau-Sallé F, Cazes A, et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 2014;33:3748-52.
118. Allory Y, Beukers W, Sagrera A, Flández M, Marqués M. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65:360-6.
119. Griewank KG, Schilling B, Murali R, Bielefeld N, Schwamborn M, Sucker A, et al. TERT promotermutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol 2014;27:502-8.
120. Zhao Y, Gao Y, Chen Z, Hu X, Zhou F, He J. Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas. Int J Cancer 2014;134:493-4.
121. Xing M, Liu R, Liu X, Murugan AK, Zhu G. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 2014;32: 2718-26.
122. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, et al. TERT promotermutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 2014;99:E1130-6.
123. Liu T, Brown TC, Juhlin CC, Andreasson A, Wang N, Bäckdahl M, et al. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer 2014;21:427-34.
124. Cárcano FM, Vidal DO, van Helvoort Lengert A, Neto CS, Queiroz L, Marques H, et al. Hotspot TERT promoter mutations are rare events in testicular germ cell tumors. Tumour Biol. 2015 Nov 3. [Epub ahead of print].
125. Oh J-E, Ohta T, Nonoguchi N, Satomi K, Capper D, Pierscianek D, et al. Genetic alterations in gliosarcoma and giant cell glioblastoma. Brain Pathol 2015 Oct 7. [Epub ahead of print].
126. Griewank KG, Murali R, Schilling B, Schimming T, Möller I, Moll I, et al. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One 2013;8:e80354-4.
127. Huang H-N, Chiang Y-C, Cheng W-F, Chen C-A, Lin M-CKuo K-T. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation. Mod Pathol 2015;28:303-11.
128. Chen YL, Jeng YM, Chang CN, Lee HJ, Hsu HC, Lai PL, et al. TERT promoter mutation in resectable hepatocellular carcinomas: a strong associationwith hepatitis Cinfection and absence of hepatitis B infection. Int J Surg 2014;12:659-65.
129. Cevik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol 2015;21:311-7.
130. Dono M, Angelini G, Cecconi M, Amaro A, Esposito AI, Mirisola V, et al. Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. Br J Cancer 2014;110:1058-65.
131. Liau JY, Tsai JH, Jeng YM, Chu CY, Kuo KT, Liang CW. TERT promoter mutation is uncommon in acral lentiginous melanoma. J Cutan Pathol 2014;41:504-8.
132. Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, et al. TERT promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms. Sci Rep 2015;5:11200.
133. Jangard M, Zebary A, Ragnarsson-Olding B, Hansson J. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases. Melanoma Res 2015;25:185-8.
134. Macerola E, Loggini B, Giannini R, Garavello G, Giordano M, Proietti A, et al. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch 2015;467:177-84.
135. Koopmans AE, Ober K, Dubbink HJ, Paridaens D, Naus NC, Belunek S, et al. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci 2014;55:6024-30.
136. Chindris A-M, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, et al. Clinical and molecular features of Hürthle cell carcinoma of the thyroid. J Clin Endocrinol Metab 2015;100:55-62.
137. Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu X, et al. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab 2015;100:E632-7.
138. Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, Perrino M, et al. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol Cell Endocrinol 2015;399:288-95.
139. Fredriksson NJ, Ny L, Nilsson JA, Larsson E. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat Genet 2014;46:1258-63.
140. Liu R, Xing M. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocr Relat Cancer 2014;21: 825-30.
141. Qasem E, Murugan AK, Al-Hindi H, Xing M, Almohanna M, Alswailem M, et al. TERT promotermutations in thyroid cancer: a report from a Middle Eastern population. Endocr Relat Cancer 2015;22:901-8.
142. Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, et al. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocr Relat Cancer 2015;22:419-29.